Please login to the form below

Not currently logged in
Email:
Password:

RDX5791

This page shows the latest RDX5791 news and features for those working in and with pharma, biotech and healthcare.

Latest Intelligence

  • Pharma deals during October 2012 Pharma deals during October 2012

    RDX5791 is an orally administered inhibitor of NHE3, a protein essential in the absorption of sodium in the intestines. ... 572. Ardelyx / AstraZeneca. Licence. RDX5791 for end stage renal and chronic kidney disease and IBS-C (phase II).

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OUTiCO

Providing an exceptional outsourcing service to the Pharma & Healthcare industries. We offer a sustainable approach and drive sales outcomes...

Latest intelligence

The relevance of patient perspectives to value
Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....
How is the NHS Long-term Plan being put into action?
Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the changes that have occurred since the plan was published...
real world studies
The evolution of real-world studies
How industry and regulators are using real-world data...

Infographics